A bivalent antihypertensive vaccine targeting L-type calcium channels and angiotensin AT₁ receptors.

ABSTRACT:

Background and purpose

Hypertension has been the leading preventable cause of premature death worldwide. The aim of this study was to design a more efficient vaccine against novel targets for the treatment of hypertension.

Experimental approach

The epitope CE12, derived from the human L-type calcium channel (Ca_V 1.2), was designed and conjugated with Qβ bacteriophage virus-like particles to test the efficacy in hypertensive animals. Further, the hepatitis B core antigen (HBcAg)-CE12-CQ10 vaccine, a bivalent vaccine based on HBcAg virus-like particles and targeting both human angiotensin AT₁ receptors and Ca_V 1.2 channels, was developed and evaluated in hypertensive rodents.

Key results

The Qβ-CE12 vaccine effectively decreased the BP i

SUBMITTER: Wu H 

PROVIDER: S-EPMC6989956 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature